Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada

por Herder, Matthew
Publicado 2016

What Is the Purpose of the Orphan Drug Act?

por Herder, Matthew
Publicado 2017

Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency

por HERDER, MATTHEW
Publicado 2019

The speakers’ bureau system: a form of peer selling

por Reid, Lynette, Herder, Matthew
Publicado 2013

Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997–2012

por Herder, Matthew, Krahn, Timothy Mark
Publicado 2016

On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data

por Pappin, Jessie, Bavli, Itai, Herder, Matthew
Publicado 2022

From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine

por Herder, Matthew, Graham, Janice E, Gold, Richard
Publicado 2020

Optimizing the data available via Health Canada’s clinical information portal

por Egilman, Alexander C., Ross, Joseph S., Herder, Matthew
Publicado 2021

Optimiser les données accessibles dans le portail de renseignements cliniques de Santé Canada

por Egilman, Alexander C., Ross, Joseph S., Herder, Matthew
Publicado 2021

University Technology Transfer Has Failed to Improve Access to Global Health Products during the COVID-19 Pandemic

por Herder, Matthew, Gold, E. Richard, Murthy, Srinivas
Publicado 2022

Authors' Response – A Status Quo of Failure: Time to Fix University Technology Transfer to Address Global Health

por Herder, Matthew, Gold, E. Richard, Murthy, Srinivas
Publicado 2022

’More of the same, but worse than before’: A qualitative study of the challenges encountered by people who use drugs in Nova Scotia, Canada during COVID-19

por Comeau, Emilie, Bonn, Matthew, Wildeman, Sheila, Herder, Matthew
Publicado 2023

From sandbox to pandemic: Agile reform of Canadian drug regulation()

por Eren Vural, Ipek, Herder, Matthew, Graham, Janice E.
Publicado 2021

Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)

por Eadie, Ashley L., Brunt, Keith R., Herder, Matthew
Publicado 2021

Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 Pandemic

por Eren Vural, Ipek, Herder, Matthew, Doll, Agnieszka, Graham, Janice E.
Publicado 2023

Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19

por Lexchin, Joel, Graham, Janice, Herder, Matthew, Jefferson, Tom, Lemmens, Trudo
Publicado 2020

Against vaccine assay secrecy

por Herder, Matthew, Hatchette, Todd F, Halperin, Scott A, Langley, Joanne M
Publicado 2015

Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015

por MacGregor, Andrea, Zhang, Audrey D., Wallach, Joshua D., Ross, Joseph S., Herder, Matthew
Publicado 2020

Reducing barriers to accessing administrative data on SARS-CoV-2 vaccination for research

por McRae, Andrew D., Archambault, Patrick, Fok, Patrick, Wiemer, Hana, Morrison, Laurie J., Herder, Matthew
Publicado 2022

Faciliter l’accès aux données administratives sur la vaccination anti-SRAS-CoV-2 aux fins de la recherche

por McRae, Andrew D., Archambault, Patrick, Fok, Patrick, Wiemer, Hana, Morrison, Laurie J., Herder, Matthew
Publicado 2022